Suda Pharmaceuticals Ltd Insider ownership
What is the Insider ownership of Suda Pharmaceuticals Ltd?
The Insider ownership of Suda Pharmaceuticals Ltd is 13.19%
What is the definition of Insider ownership?
Insider Ownership is calculated as the total number of shares owned by insiders (shareholders who own more than 5% of the corporation or an officer or director of the company) divided by the total Shares Outstanding.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Insider ownership of companies in the Health Care sector on ASX compared to Suda Pharmaceuticals Ltd
What does Suda Pharmaceuticals Ltd do?
Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Companies with insider ownership similar to Suda Pharmaceuticals Ltd
- Braille Systems has Insider ownership of 13.15%
- Mesoblast has Insider ownership of 13.16%
- Ipsos SA has Insider ownership of 13.16%
- Creative Media & Community Trust has Insider ownership of 13.16%
- Aurion Resources has Insider ownership of 13.18%
- Touchstone Exploration has Insider ownership of 13.18%
- Suda Pharmaceuticals Ltd has Insider ownership of 13.19%
- ANI Pharmaceuticals Inc has Insider ownership of 13.20%
- BNP Paribas SA has Insider ownership of 13.20%
- Scorpio Tankers Inc has Insider ownership of 13.20%
- Lundin Mining has Insider ownership of 13.20%
- St George Mining has Insider ownership of 13.21%
- Alerus has Insider ownership of 13.21%